JNJ Cashes New Merck Out — Of Their Consumer Health JV


This is a few days old, but it will complete the record, here — just couldn’t get to it before (as a new graphic was needed). From BusinessWeek, of September 28, 2011 then:

. . . .Johnson & Johnson bought Merck & Co.’s half of the companies’ joint venture for over-the-counter medicines for heartburn and digestive diseases for $175 million, ending a 22-year partnership in the U.S. and Canada.

The deal. . . includes a manufacturing plant in Lancaster, Pennsylvania, that is part of a consent decree with U.S. regulators because of production violations. J&J, the world’s second-biggest seller of health products after Pfizer Inc., has recalled dozens of drugs and devices in the past two years, including nonprescription medicines such as Tylenol. . . .

So it goes — this still leaves the recently-restructured prescription relationship on Simponi® (golimumab)/Remicade® in place between the companies, however — post the arbitration settlement.

Now, Whitehouse Station says New Merck will be freed up to focus upon its legacy Schering-Plough Consumer Health offerings. We shall see.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s